Theolytics

Theolytics is a clinical-stage biotech founded in 2017 in Oxford, UK, focused on developing next-generation oncolytic virus therapies for solid tumors. Its core innovation is the ADENOVO platform, which uses Darwinian selection on actual patient tumors to identify viruses optimized for efficacy, delivery, and manufacturing. With a lead candidate in Phase 1/2 trials for ovarian cancer and a pipeline targeting other indications, the company aims to overcome the significant barriers posed by the tumor stroma and microenvironment.

ADENOVO platform: a proprietary discovery engine that uses Darwinian natural selection on vast libraries of adenovirus variants (>100 million) within actual patient tumor samples to identify optimized oncolytic immunotherapies. It selects for efficacy against cancer cells and stroma, ability to reshape the immune microenvironment, suitability for IV/direct delivery, and manufacturability.

Theolytics competes in the oncolytic virus segment with companies like Amgen (Imlygic), DNAtrix, and Turnstone Biologics, as well as broader immuno-oncology players. Its key differentiators are the ADENOVO platform's selection process in patient tumors, a explicit focus on destroying the tumor stroma, and the development of candidates suitable for intravenous administration, which could provide a competitive edge in treating systemic disease.